FDA inspection
Baltimore Washington Medical Center: FDA inspection ending Feb 2, 2001
FDA inspection 60403 · No Action Indicated (NAI) · Glen Burnie, MD
Key facts
| Inspection ID | 60403 |
|---|---|
| Firm | Baltimore Washington Medical Center |
| FEI number | 1173722 |
| Address | 301 Hospital Dr |
| City | Glen Burnie |
| State | MD |
| ZIP | 21061-5803 |
| Fiscal year | 2001 |
| Inspection end date | Feb 2, 2001 |
| Classification | No Action Indicated (NAI) |
| Project area | Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation|Blood and Blood Products|New Drug Evaluation |
| Product type | Biologics, Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data